- Home
- Publications
- Publication Search
- Publication Details
Title
A review on development of MUC1-based cancer vaccine
Authors
Keywords
MUC1-based vaccine, Clinical trials, Infection-associated cancers
Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 132, Issue -, Pages 110888
Publisher
Elsevier BV
Online
2020-10-21
DOI
10.1016/j.biopha.2020.110888
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Latest developments in MUC1 immunotherapy
- (2018) Joyce Taylor-Papadimitriou et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect
- (2018) Chenlu Liu et al. IMMUNOLOGY LETTERS
- MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model
- (2018) C. Liu et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Dendritic Cell-Based Immunotherapy for Solid Tumors
- (2018) Nam-Chul Jung et al. Translational Oncology
- Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid
- (2018) Natascha Stergiou et al. Cancer Immunology Research
- Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy
- (2017) Yuan-Feng Gong et al. Oncology Letters
- A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer
- (2016) Björn Palitzsch et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas
- (2016) Pamela L. Beatty et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant
- (2016) Junzhong Ruan et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Pre-clinical toxicity and immunogenicity evaluation of a MUC1–MBP/BCG anti-tumor vaccine
- (2016) Boqi Hu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
- (2016) Elisabeth Quoix et al. LANCET ONCOLOGY
- MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model
- (2016) Haihong Zhang et al. VACCINE
- Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment
- (2016) Nuria Martínez-Sáez et al. Chemical Science
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer
- (2016) E. Scheid et al. Cancer Immunology Research
- Update on Mucin-1 immunotherapy in cancer: a clinical perspective
- (2015) Gareth Rivalland et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Synthetic Multivalent Glycopeptide-Lipopeptide Antitumor Vaccines: Impact of the Cluster Effect on the Killing of Tumor Cells
- (2014) Hui Cai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- MUC1 and maltose-binding protein recombinant fusion protein combined with Bacillus Calmette-Guerin induces MUC1-specific and nonspecific anti-tumor immunity in mice
- (2014) FANG FANG et al. Molecular Medicine Reports
- MUC1: a multifaceted oncoprotein with a key role in cancer progression
- (2014) Sritama Nath et al. TRENDS IN MOLECULAR MEDICINE
- Self-Adjuvanting Synthetic Antitumor Vaccines from MUC1 Glycopeptides Conjugated to T-Cell Epitopes from Tetanus Toxoid
- (2013) Hui Cai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The development of synthetic antitumour vaccines from mucin glycopeptide antigens
- (2013) Nikola Gaidzik et al. CHEMICAL SOCIETY REVIEWS
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
- (2012) Carl Christoph Schimanski et al. BMC CANCER
- MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study
- (2012) T. Kimura et al. Cancer Prevention Research
- MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 1,6-N-acetylglucosaminyltransferase and -galactoside 2,3-sialyltransferase
- (2012) A. Solatycka et al. GLYCOBIOLOGY
- Cyclooxygenase-2 Enzyme Induces the Expression of the α-2,3-Sialyltransferase-3 (ST3Gal-I) in Breast Cancer
- (2012) Daisy Sproviero et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+T cells
- (2012) Atsushi Nishida et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Synthetic Antitumor Vaccines Containing MUC1 Glycopeptides with Two Immunodominant Domains-Induction of a Strong Immune Response against Breast Tumor Tissues
- (2011) Nikola Gaidzik et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- MUC1 Protein Expression in Tumor Cells Regulates Transcription of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters
- (2011) Sandra Cascio et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial
- (2011) Charles Butts et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- MUC1-C Oncoprotein Regulates Glycolysis and Pyruvate Kinase m2 Activity in Cancer Cells
- (2011) Michio Kosugi et al. PLoS One
- Synergistic antitumor effects of Escherichia coli maltose binding protein and Bacillus Calmette–Guerin in a mouse lung carcinoma model
- (2010) Qingyong Zhang et al. IMMUNOLOGY LETTERS
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
- (2010) Susanne M Rittig et al. MOLECULAR THERAPY
- A Synthetic Vaccine Consisting of a Tumor-Associated Sialyl-TN-MUC1 Tandem-Repeat Glycopeptide and Tetanus Toxoid: Induction of a Strong and Highly Selective Immune Response
- (2009) Anton Kaiser et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience
- (2009) Jianglong Zhu et al. Expert Review of Vaccines
- Synthetic Vaccines Consisting of Tumor-Associated MUC1 Glycopeptide Antigens and a T-Cell Epitope for the Induction of a Highly Specific Humoral Immune Response
- (2008) Ulrika Westerlind et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
- (2008) J Creaney et al. BRITISH JOURNAL OF CANCER
- Signaling defects in anti-tumor T cells
- (2008) Alan B. Frey et al. IMMUNOLOGICAL REVIEWS
- MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
- (2008) R. Dreicer et al. INVESTIGATIONAL NEW DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started